Research work · 2018

Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial

Carol Moreno, Richard Greil, Fatih Demırkan, Alessandra Tedeschi, Bertrand Marquess Anz, Loree M. Larratt, Martin Šimkovič, Olga S. Samoilova, Jan Novák, Dina Ben‐Yehuda, Vladimir Vladimirovich Strugov, Devinder Singh Gill, John G. Gribben, Emily Hsu, Chih‐Jian Lih, Cathy Zhou, Fong Clow, Danelle Frances James, Lori Appel Styles, Ian W. Flinn

The Lancet Oncology

DOI: 10.1016/s1470-2045(18)30788-5